IBDEI02P ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3176,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,3177,0)
 ;;=286.7^^32^211^45
 ;;^UTILITY(U,$J,358.3,3177,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3177,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,3177,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,3177,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,3178,0)
 ;;=289.9^^32^211^108
 ;;^UTILITY(U,$J,358.3,3178,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3178,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,3178,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,3178,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,3179,0)
 ;;=451.9^^32^211^109
 ;;^UTILITY(U,$J,358.3,3179,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3179,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,3179,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,3179,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,3180,0)
 ;;=446.6^^32^211^110
 ;;^UTILITY(U,$J,358.3,3180,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3180,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,3180,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,3180,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,3181,0)
 ;;=286.4^^32^211^113
 ;;^UTILITY(U,$J,358.3,3181,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3181,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,3181,1,5,0)
 ;;=5^Von Willebrand'S Disease
 ;;^UTILITY(U,$J,358.3,3181,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,3182,0)
 ;;=204.00^^32^211^5
 ;;^UTILITY(U,$J,358.3,3182,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3182,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,3182,1,5,0)
 ;;=5^All, W/O Remission
 ;;^UTILITY(U,$J,358.3,3182,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,3183,0)
 ;;=204.01^^32^211^4
 ;;^UTILITY(U,$J,358.3,3183,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3183,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,3183,1,5,0)
 ;;=5^All, In Remission
 ;;^UTILITY(U,$J,358.3,3183,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,3184,0)
 ;;=204.10^^32^211^42
 ;;^UTILITY(U,$J,358.3,3184,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3184,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,3184,1,5,0)
 ;;=5^Cll, W/O Remission
 ;;^UTILITY(U,$J,358.3,3184,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,3185,0)
 ;;=204.11^^32^211^41
 ;;^UTILITY(U,$J,358.3,3185,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3185,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,3185,1,5,0)
 ;;=5^Cll, In Remission
 ;;^UTILITY(U,$J,358.3,3185,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,3186,0)
 ;;=201.90^^32^211^72
 ;;^UTILITY(U,$J,358.3,3186,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3186,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,3186,1,5,0)
 ;;=5^Hodgkin'S Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,3186,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,3187,0)
 ;;=785.6^^32^211^79
 ;;^UTILITY(U,$J,358.3,3187,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3187,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,3187,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,3187,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,3188,0)
 ;;=200.20^^32^211^80
 ;;^UTILITY(U,$J,358.3,3188,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3188,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,3188,1,5,0)
 ;;=5^Lymphoma, Burkitt'S, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,3188,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,3189,0)
 ;;=202.00^^32^211^82
 ;;^UTILITY(U,$J,358.3,3189,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3189,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,3189,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,3189,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,3190,0)
 ;;=200.10^^32^211^81
 ;;^UTILITY(U,$J,358.3,3190,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3190,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,3190,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,3190,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,3191,0)
 ;;=273.3^^32^211^83
 ;;^UTILITY(U,$J,358.3,3191,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3191,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,3191,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,3191,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,3192,0)
 ;;=203.00^^32^211^92
 ;;^UTILITY(U,$J,358.3,3192,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3192,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,3192,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,3192,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,3193,0)
 ;;=203.01^^32^211^91
 ;;^UTILITY(U,$J,358.3,3193,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3193,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,3193,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,3193,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,3194,0)
 ;;=238.6^^32^211^95
 ;;^UTILITY(U,$J,358.3,3194,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3194,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,3194,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,3194,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,3195,0)
 ;;=205.00^^32^211^7
 ;;^UTILITY(U,$J,358.3,3195,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3195,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,3195,1,5,0)
 ;;=5^Aml, W/O Remission
 ;;^UTILITY(U,$J,358.3,3195,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,3196,0)
 ;;=205.01^^32^211^6
 ;;^UTILITY(U,$J,358.3,3196,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3196,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,3196,1,5,0)
 ;;=5^Aml, In Remission
 ;;^UTILITY(U,$J,358.3,3196,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,3197,0)
 ;;=205.10^^32^211^44
 ;;^UTILITY(U,$J,358.3,3197,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3197,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,3197,1,5,0)
 ;;=5^Cml, W/O Remission
 ;;^UTILITY(U,$J,358.3,3197,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,3198,0)
 ;;=205.11^^32^211^43
 ;;^UTILITY(U,$J,358.3,3198,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3198,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,3198,1,5,0)
 ;;=5^Cml, In Remission
 ;;^UTILITY(U,$J,358.3,3198,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,3199,0)
 ;;=289.0^^32^211^46
 ;;^UTILITY(U,$J,358.3,3199,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3199,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,3199,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,3199,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,3200,0)
 ;;=238.4^^32^211^96
 ;;^UTILITY(U,$J,358.3,3200,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3200,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,3200,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,3200,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,3201,0)
 ;;=V58.61^^32^211^114
 ;;^UTILITY(U,$J,358.3,3201,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3201,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,3201,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,3201,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,3202,0)
 ;;=282.49^^32^211^106
 ;;^UTILITY(U,$J,358.3,3202,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3202,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,3202,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,3202,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,3203,0)
 ;;=289.89^^32^211^14
 ;;^UTILITY(U,$J,358.3,3203,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3203,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,3203,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,3203,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,3204,0)
 ;;=238.79^^32^211^77
 ;;^UTILITY(U,$J,358.3,3204,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3204,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,3204,1,5,0)
 ;;=5^LYMPH/HEMATPOITC TIS NEC
 ;;^UTILITY(U,$J,358.3,3204,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,3205,0)
 ;;=287.30^^32^211^97
 ;;^UTILITY(U,$J,358.3,3205,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3205,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,3205,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,3205,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,3206,0)
 ;;=288.09^^32^211^3
 ;;^UTILITY(U,$J,358.3,3206,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3206,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,3206,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,3206,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,3207,0)
 ;;=V10.21^^32^211^52
 ;;^UTILITY(U,$J,358.3,3207,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3207,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,3207,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,3207,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,3208,0)
 ;;=284.2^^32^211^93
 ;;^UTILITY(U,$J,358.3,3208,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3208,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,3208,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,3208,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,3209,0)
 ;;=202.40^^32^211^65
 ;;^UTILITY(U,$J,358.3,3209,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3209,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,3209,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,3209,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,3210,0)
 ;;=287.49^^32^211^107
 ;;^UTILITY(U,$J,358.3,3210,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3210,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,3210,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,3210,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,3211,0)
 ;;=285.9^^32^211^1
 ;;^UTILITY(U,$J,358.3,3211,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3211,1,4,0)
 ;;=4^285.9
 ;;^UTILITY(U,$J,358.3,3211,1,5,0)
 ;;=5^ANEMIA NOS
 ;;^UTILITY(U,$J,358.3,3211,2)
 ;;=^7007
 ;;^UTILITY(U,$J,358.3,3212,0)
 ;;=785.6^^32^211^78
 ;;^UTILITY(U,$J,358.3,3212,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3212,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,3212,1,5,0)
 ;;=5^LYMPHADENOPATHY
 ;;^UTILITY(U,$J,358.3,3212,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,3213,0)
 ;;=465.9^^32^212^64
 ;;^UTILITY(U,$J,358.3,3213,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3213,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,3213,1,5,0)
 ;;=5^URI
 ;;^UTILITY(U,$J,358.3,3213,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,3214,0)
 ;;=599.0^^32^212^65
 ;;^UTILITY(U,$J,358.3,3214,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,3214,1,4,0)
 ;;=4^599.0
 ;;^UTILITY(U,$J,358.3,3214,1,5,0)
 ;;=5^UTI
 ;;^UTILITY(U,$J,358.3,3214,2)
 ;;=UTI^124436
